The global chronic hepatitis B treatment market is experiencing significant expansion. This movement can be linked to a rising of factors, including an increasing population, improved diagnostic capabilities, and rising awareness about the disease. The market is moreover driven by advancements in treatment approaches, such as antiviral medications.